A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors (NCT07318805)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to learn about the safety and effects of the study medicine when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment to stop the growth of cancer. This study also aims to find the best amount of study medication. This study is seeking participants that have advanced or metastatic breast cancer (BC), or advanced or metastatic colorectal cancer (CRC). All participants in this study will take the study medication (PF-08032562) as pill by mouth. This will be repeated for 28-day cycles. Depending on which part of the study participants are enrolled into, they will receive the study medication PF-08032562 alone or in combination with other anti-cancer medications. The study medication (PF-08032562) will be taken by mouth (PO) in combination with other anti-cancer medications given in the study clinic by intramuscular (IM) injection into the muscle or intravenous (IV) infusion that is directly injected into the veins at different times (depending on the treatment) during the 28-day cycle. The study may also test different schedules.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (4 items) and avoid the listed exclusions (12 items).
Location: City of Hope (City of Hope National Medical Center, City of Hope Medical Center) — Duarte, California
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Active malignancy within 3 years prior to enrollment
- Known symptomatic brain metastases requiring steroids
- Advanced/metastatic, symptomatic, visceral spread, that are at risk of life-threatening complications in the short term
- Prior irradiation to \>25% of the bone marrow
- Hypertension that cannot be controlled by optimal medical therapy
- Renal impairment
- Hepatic dysfunction
- Cardiac abnormalities
- Active bleeding disorder
- Active or history of clinically significant GI disease
- Other unacceptable abnormalities as defined by protocol
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (13 Sites)
- City of Hope (City of Hope National Medical Center, City of Hope Medical Center) — Duarte, California
- START Midwest, LLC — Grand Rapids, Michigan
- Memorial Sloan Kettering Cancer Center - Investigational Drug Service Pharmacy — Long Island City, New York
- Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street). — New York, New York
- Memorial Sloan Kettering Cancer Center 53rd street. — New York, New York
- Memorial Sloan Kettering Cancer Center - Main Campus — New York, New York
- The University of Texas MD Anderson Cancer Center - Conroe — Conroe, Texas
- The University of Texas - M.D. Anderson Cancer Center — Houston, Texas
- The University of Texas, MD Anderson Cancer Center - West Houston — Houston, Texas
- The University of Texas, MD Anderson Cancer Center - League City — League City, Texas
- START San Antonio — San Antonio, Texas
- The University of Texas, MD Anderson Cancer Center - Sugar Land — Sugar Land, Texas
- START Mountain Region — West Valley City, Utah
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.